The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

This publication has 19 references indexed in Scilit:

• In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF)
  Annals of Hematology, 2002
• Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment
  Blood, 2002
• Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
  Journal of Clinical Oncology, 2002
• Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine
  British Journal of Haematology, 2001
• Colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes
  Leukemia, 2000
• Spontaneous and cytokine‐induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology
  British Journal of Haematology, 1999
• Risks, Costs, and Alternatives to Platelet Transfusions
  Leukemia & Lymphoma, 1999
• Pilot phase l-ll study on 5-aza-2??-deoxycytidine (Decitabine) in patients with metastatic lung cancer
  Anti-Cancer Drugs, 1997
• Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
  Leukemia, 1997
• Treatment of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating Factor
  Annals of Internal Medicine, 1989